로딩 중…
지수 로딩 중…
Mineralys Therapeutics, Inc.
MLYS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$25.78+1.02%
2026-08-03
Financials
Valuation Metrics
Mineralys Therapeutics, Inc.'s Market Cap is $2.13B. At end of 2025 it was $2.92B. Ranked #2009 of 3,112 in US market (top 65%), #761 of 1,445 on NASDAQ (top 53%), #129 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.13B | US#2,009/3,112 Sec#129/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-152M | US—/3,112 Sec—/269 |
| Total Assets | $653M | US#2,638/3,112 Sec#130/269 |
| Net Assets | $638M | US#2,081/3,112 Sec#88/269 |
| Value | ||
| P/B | 3.33x | US#1,800/3,112 Sec#103/269 |
| FCF Yield | -6.41% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -23.78% | US#2,566/3,112 Sec#112/269 |
| ROA | -23.25% | US#2,812/3,112 Sec#137/269 |
| Financial Health | ||
| Debt Ratio | 2.31% | US#20/3,112 Sec#3/269 |
| Total Debt | $0.00 | US—/3,112 Sec—/269 |
| FCF | $-136M | US#2,663/3,112 Sec#181/269 |
| Cash | $113M | US#2,152/3,112 Sec#169/269 |
| Current Ratio | 44.33x | US#55/3,112 Sec#3/269 |
| Performance | ||
| 1Y Return | 88.59% | US#324/3,112 Sec#84/269 |
| 1M Return | -6.90% | US#2,407/3,112 Sec#139/269 |
| From 52W High | -45.90% | US#2,694/3,112 Sec#208/269 |
| 1Y MDD | -52.46% | US#2,499/3,112 Sec#193/269 |
| Trading | ||
| Volume | 979,503 shares | US#1,488/3,112 Sec#147/269 |
| Trading Value | $25M | US#1,841/3,112 Sec#130/269 |
| Per Share | ||
| EPS | $-1.92 | US—/3,112 Sec—/269 |
| BPS | $8.03 | US#1,937/3,112 Sec#83/269 |